Ocugen

OCGN

Market cap $548M

MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at Oppenheimer's 3rd Annual Innovation on the Island Biotech Summit from April 27-29, 2026 in Rio Grande, Puerto Rico; and Abhi Gupta, MBA, Executive Vice President, Commercial and Business Development at Ocugen will present at the 2026 Cell & Gene Meeting on the Mediterranean being held April 28-30, 2026 in Rome, Italy.

Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.

Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.

Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal gene therapies.

Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock?

Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments. Data readouts are expected in Q3.

MALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate developed for all Stargardt disease (ABCA4-associated retinopathies).

OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.

Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript

OCU410 is an investigational gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).